Table 2.
Characteristics and quality analysis of studies included in the meta-analysis.
| Author, year | No. of patients (total) | Etiology of liver fibrosis | Pharmacological intervention | Control | Duration | Design | Jadad score |
|---|---|---|---|---|---|---|---|
| Terui Y, 200230 | 30 | 30 viral liver disease | Losartan 50 mg/d plus UDCA 600 mg/d | UDCA 600 mg/d | N/A | RCT | 2 |
| Debernardi-Venon W, 200740 | 47 | 40 viral and 7 alcohol liver disease | Candesartan 8mg/d | No treatment | 12 mo | RCT | 5 |
| Hidaka H, 201143 | 48 | 31 viral, 9 alcohol liver disease and 8 others | Olmesartan 10–40 mg/d (10 to 20 then to 40 mg) | No treatment | 12 mo | RCT | 5 |
| Kim MY, 201244 | 85 | 85 alcohol liver disease | Candesartan 8mg/d plus UDCA 600mg/d | UDCA 600 mg/d | 6 mo | RCT | 5 |
N/A, data not available; UDCA, ursodeoxycholic acid.